NCT00829426View on ClinicalTrials.gov

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Healthy
Interventions
DRUG

Alprazolam Extended-Release 3 mg Tablets

1 x 3 mg, single dose fasting

DRUG

Alprazolam Extended-Release 3 mg Tablets

1 x 3 mg, single dose fasting

Trial Locations (2)

56721

PRACS Institute, Ltd., East Grand Forks

58104

PRACS Institute, Ltd., Fargo

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT00829426 - Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions | Biotech Hunter | Biotech Hunter